Erhalten Sie eine woechentliche Zusammenfassung der neuesten psychedelischen Forschung, neuer Studien und Plattform-Updates direkt in Ihren Posteingang.
Kein Spam, nie. Jederzeit abbestellbar.
Substanzprofil
Ibogain ist ein natürlich vorkommendes Indol-Alkaloid aus der Wurzelrinde des westafrikanischen Strauchs Tabernanthe iboga. Es besitzt ein einzigartiges, komplexes Multi-Target-Wirkprofil mit Aktivität an NMDA-, Opioid-, Serotonin- und Nikotinrezeptoren. In der Bwiti-Tradition Gabuns wird es seit Jahrhunderten als Sakrament verwendet. Ibogain hat in klinischen Studien bemerkenswerte Ergebnisse bei der Unterbrechung von Opioid-Abhängigkeit gezeigt, wobei es Entzugssymptome schnell lindert und das Verlangen reduziert. Aufgrund seiner Kardiotoxizität (QT-Verlängerung) erfordert die Anwendung strikte medizinische Überwachung.
Modulates NMDA, opioid, serotonin, and nicotinic receptors simultaneously
Resets opioid receptor sensitivity via GDNF upregulation
Cardiac risk — blocks potassium channels causing QT prolongation
Berichtete subjektive Effekte basierend auf klinischen und Community-Daten
Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention.
Changes in synaptic markers after administration of ketamine or psychedelics: a systematic scoping review.
Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration.
Rare but relevant: Ibogaine and cardiovascular complications-prolonged QT interval and ventricular arrhythmias.
Mapping Ibogaine Neural Dynamics in Opioid Use Disorder
Disrupting Substance Use Disorder: The Chemistry of Iboga Alkaloids.
Use of Psychedelic Agents in Older Adults with Treatment-Resistant Major Depressive Disorder: What the Evidence Shows.
Psychedelics, entactogens and psychoplastogens for depression and related disorders.
Efficient and modular synthesis of ibogaine and related alkaloids.
The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies.
Not Losing Momentum: Cross-Sectional Insights into Ibogaine Clinical Trials.
Psychedelic-assisted treatment for substance use disorder: A narrative systematic review.
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.
Traditional Medicine, Culture, and Psychedelic Science: New Pathways for Recovery From Substance Use Disorders.
Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models.
Benzofuran Iboga-Analogs Modulate Nociception and Inflammation in an Acute Mouse Pain Model.
Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder - a narrative review.
What is needed for the roll-out of psychedelic treatments?
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.
Set and setting predict psychopathology, wellbeing and meaningfulness of psychedelic experiences: a correlational study.
Neuroimaging in psychedelic drug development: past, present, and future.
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview.
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies.
Structure-based discovery of conformationally selective inhibitors of the serotonin transporter.
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
What We Have Gained from Ibogaine: α3β4 Nicotinic Acetylcholine Receptor Inhibitors as Treatments for Substance Use Disorders.
Ibogaine in the Treatment of Alcoholism: an Open-label Escalating-dose Trial
The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020).
A systematic literature review of clinical trials and therapeutic applications of ibogaine.
Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse.
The iboga enigma: the chemistry and neuropharmacology of iboga alkaloids and related analogs.
A non-hallucinogenic psychedelic analogue with therapeutic potential.
Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification
[Neurotrophic mechanisms of psychedelic therapy].
DARK Classics in Chemical Neuroscience: Ibogaine.
Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.
Ibogaine as a treatment for substance misuse: Potential benefits and practical dangers.
Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.
Ibogaine and addiction in the animal model, a systematic review and meta-analysis.
Ibogaine for treating drug dependence. What is a safe dose?
The Iboga Alkaloids.
hERG Blockade by Iboga Alkaloids.
How toxic is ibogaine?
Ibogaine-associated cardiac arrest and death: case report and review of the literature.
Mania following use of ibogaine: A case series.
The anti-addiction drug ibogaine and the heart: a delicate relation.
Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, Peyote, Ibogaine and Ayahuasca.
Fatal case of a 27-year-old male after taking iboga in withdrawal treatment: GC-MS/MS determination of ibogaine and ibogamine in iboga roots and postmortem biological material.
Ibogaine in the treatment of substance dependence.